jmortonmd
1.6K posts
@Jmortonmd
Professor & Vice-Chair, Dedicated to Public Health via Access, Quality & Treating #Obesity, Past-President@ASMBS, Inaugural MBSAQIP Chair@AmCollSurgeons, @yale
Omada members reported 94% persistence on GLP-1s through 12 weeks and 84% through 24 weeks — higher than the drop‑off often seen in other real‑world use. We're proud to share that Medscape recently featured these exciting findings. Read more: medscape.com/viewarticle/gl… #GLP1
Please join us in welcoming Dr. C. Joe Northup, MD FACS FASMBS DABS-FPMBS, as the 40th President of ASMBS. Read Dr. Northup's message to ASMBS members here: buff.ly/vukGbaE #ASMBS #BariatricSurgery #MetabolicHealth #Healthcare #ObesityCare #IntegratedHealth #Health
AHA’s new statement gets an important point right: exercise in obesity care is not just a weight-loss tool. It preserves function, cardiometabolic health, and quality of life, including in the GLP-1 era. edhub.ama-assn.org/jn-learning/au…
Published today, the first-ever clinical practice guideline on cardiovascular-kidney-metabolic syndrome from the American Heart Association and @ACCinTouch. Cardiovascular-kidney-metabolic (CKM) syndrome staging is recommended for youths and adults to prevent CKM syndrome stage progression, to tailor therapy to absolute risk, to reduce cardiovascular events and loss of kidney function across the life course, and to promote CKM syndrome stage regression through lifestyle changes and weight loss. The diagnosis of CKM syndrome stage requires assessment of metabolic health, kidney function, and cardiovascular risk factors, which enhances the identification of frequently unrecognized or asymptomatic CKM conditions. ✍🏼 @ChiadiNdumele @HeartDocSadiya @kardiologykazi @noshreza @virani_md @biykemb @NutritionHF @mandeepbajaj65 @KatherineTuttl8 @RangaswJ @lisaVWMD @KBreathettMD @EmoryFamMed @ShoaClarke @mad_sters @jmortonmd @sripalbangalore @AnumSaeedMD
Want to be a change agent? Join us for our *FINAL* virtual info session on June 11th! Connect with current NCSP scholars and faculty. Register: tinyurl.com/NCSPInfoJune11… #ApplyNCSP @NCSP_UCLA @NCSP_UCSF @ncspMICHIGAN @NCSP_PENN @NCSP_YALE
High placebo response is a major hurdle in MASH drug development. In this meta-analysis of 127 RCTs (n=6,880), 11% of placebo patients achieved MASH resolution without fibrosis worsening, 18–26% improved key histologic features, and nearly one in five met MRI-PDFF fat reduction targets on placebo alone. Meta-regression could not identify consistent clinical or trial-level predictors of this effect, reinforcing that endpoint selection and trial design will be critical to truly distinguish drug signal from a surprisingly strong placebo response in future MASH programs. cghjournal.org/article/S1542-…
NEWS: NIH researchers identify avenue for enhanced GLP-1-induced weight loss. Read the full story ➡️ bit.ly/4tLnt8Z
The world’s most popular weight-loss and diabetes drugs are linked to a powerful new possible benefit: better outcomes for cancer patients. on.wsj.com/3RBfcXO
@Jmortonmd Thank you for being part of this discussion!
If everyone in Canada with a BMI >30 took Retatrutide, obesity would fall from 32.7% → 5.6% in one year.
